RxDoctor Payments Data

Christopher Middendorf, DO

Pain Medicine · Pensacola, FLNPI 1154593259

Payments from drug & device makers

$1,274in general payments, 2019–2025

Across 34 payments — averaging $37.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$444
  • Nevro Corp.$423
  • Boston Scientific$119
  • SPR Therapeutics, Inc$94
  • Amgen$69
  • Biodelivery Sciences International, Inc.$38
  • plus $87 from 5 others

What the payments were for

  • Food & beverage$1,25398%
  • Education$212%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,274 in reported general payments places this provider in the 40th percentile of 596 pain medicine providers in Florida.

See all pain medicine providers in Florida

Medicare billing

Part B allowed, 2024
$575,963
Medicare patients
862
Services billed
7,166

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen3,084$61,780
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen982$25,314
Gabapentin1,467$17,693
Lidocaine149$17,150
Pregabalin800$13,919
Buprenorphine56$11,640
BelbucaBuprenorphine Hcl14$9,414
LinzessLinaclotide11$8,190
Tizanidine Hcl667$7,026
MovantikNaloxegol Oxalate16$6,074
Methocarbamol524$5,055
Cyclobenzaprine Hcl452$4,447
Duloxetine Hcl372$4,244
Lidocaine-PrilocaineLidocaine/Prilocaine103$3,783
Naloxone Hcl59$3,762

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Hikma Pharmaceuticals USABuprenorphine, Morphine Sulfate$21$11,83370 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 596 pain medicine providers in Florida.

Other pain medicine in Pensacola

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →